ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that United Healthcare will cover
Optune as an adjunctive therapy for the treatment of glioblastoma (GBM)
when used according to FDA labeled indications and contraindications,
effective Jan. 1, 2017. United Healthcare administers medical benefit
plans that cover 44.7 million individuals.
As of Jan. 1, 2017, more than 177 million Americans will have coverage
of Optune, a portable, noninvasive device that delivers Tumor Treating
Fields (TTFields) therapy to patients with newly diagnosed and recurrent
GBM. As of Sept. 30, 2016, more than 130 million Americans had coverage
of Optune. United Healthcare’s positive coverage policy of Optune adds
to positive coverage policies from Harvard Pilgrim Healthcare, Oregon
Health Plan and Blue Cross Blue Shield of Arizona.
Novocure is a commercial-stage oncology company developing a novel,
proprietary therapy called Tumor Treating Fields, or TTFields, for the
treatment of solid tumor cancers. Novocure’s commercialized product,
Optune, is approved for the treatment of adult patients with
glioblastoma. Novocure has ongoing or completed phase 2 pilot trials
investigating TTFields in NSCLC, pancreatic cancer, ovarian cancer and
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the
company has offices in Germany, Switzerland and Japan, and a research
center in Haifa, Israel. For additional information about the company,
please visit www.novocure.com
or follow us at www.twitter.com/novocure.
In the United States, Optune is intended as a treatment for adult
patients (22 years of age or older) with histologically-confirmed
glioblastoma multiforme (GBM).
In the United States, Optune with temozolomide is indicated for the
treatment of adult patients with newly diagnosed, supratentorial
glioblastoma following maximal debulking surgery and completion of
radiation therapy together with concomitant standard of care
In the United States, for the treatment of recurrent GBM, Optune is
indicated following histologically-or radiologically-confirmed
recurrence in the supratentorial region of the brain after receiving
chemotherapy. The device is intended to be used as a monotherapy, and is
intended as an alternative to standard medical therapy for GBM after
surgical and radiation options have been exhausted.
In the European Union, Optune is intended for the treatment of patients
with newly diagnosed GBM, after surgery and radiotherapy with adjuvant
temozolomide, concomitant to maintenance temozolomide. The treatment is
intended for adult patients, 18 years of age or older, and should be
started more than four weeks after surgery and radiation therapy with
adjuvant temozolomide. Treatment may be given together with maintenance
temozolomide and after maintenance temozolomide is stopped.
In the European Union, Optune is also intended for the treatment of
patients with recurrent GBM who have progressed after surgery,
radiotherapy and temozolomide treatment for their primary disease. The
treatment is intended for adult patients, 18 years of age or older, and
should be started more than 4 weeks after the latest surgery, radiation
therapy or chemotherapy.
Patients should only use Optune under the supervision of a physician
properly trained in use of the device. Full prescribing information is
available at www.optune.com/safety
or by calling toll free 1-855-281-9301 in the US or by email at supportEMEA@novocure.com
in the European Union.
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, development of potential
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects
for its products, and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe" or other
words and terms of similar meaning. Novocure's performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and
Exchange Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements.
Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.